Skip to content

XOMA Corporation XOMA Enterprise value

Enterprise value at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.87B+95.4%
Royalty Pharma logo
Royalty PharmaRPRX
$28.94B+44.6%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$588.13M+55.1%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$1.39B+9.7%
Zymeworks logo
ZymeworksZYME
$1.63B+112%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.83B-51.1%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$745.16M+159%
P/E22×
P/S15.4×+8.6×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Calculated from XOMA Corporation’s reported figures.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's enterprise value?
XOMA Corporation (XOMA) reported enterprise value of $412.61M in Q1 2026.
How has XOMA Corporation's enterprise value changed year-over-year?
XOMA Corporation's enterprise value increased by 56.9% year-over-year, from $262.92M to $412.61M.
What is the long-term trend for XOMA Corporation's enterprise value?
Over 5 years (2020 to 2025), XOMA Corporation's enterprise value has grown at a -2.8% compound annual growth rate (CAGR), from $436.2M to $377.94M.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.